Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : GSK save search
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
Published: 2024-02-07 (Crawled : 12:00) - globenewswire.com
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.43%
H: 0.67%
C: 0.21%
ALEC | $5.1 0.2% 0.2% 470K
|
Health Technology
|
| O: 2.15%
H: 5.51%
C: 3.73%
fda dementia designation grants therapy
US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
Published: 2023-05-03 (Crawled : 23:00) - biospace.com/
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 1.24%
H: 1.14%
C: 0.11%
AGEN | $5.3 6.64% 6.23% 1.5M
|
Health Technology
|
| O: 1.42%
H: 6.99%
C: 4.2%
fda vaccine respiratory virus
US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer
Published: 2023-02-10 (Crawled : 08:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -2.43%
H: 0.66%
C: 0.66%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.07%
H: 0.06%
C: -0.55%
ANAB | $19.865 0.18% 0.18% 290K
|
Health Technology
|
| O: 0.04%
H: 1.27%
C: -0.62%
treatment fda grants approval cancer
GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis
Published: 2022-07-27 (Crawled : 20:00) - biospace.com/
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.56%
H: 3.36%
C: 2.98%
fda active lupus approval
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg
Published: 2022-03-29 (Crawled : 18:00) - biospace.com/
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: -1.87%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
fda approval hiv order
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment
Published: 2022-02-01 (Crawled : 14:30) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.09%
H: 0.8%
C: 0.63%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.45%
H: 0.53%
C: 0.42%
treatment fda health fda approval thc approval hiv
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
Published: 2022-01-13 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: 0.38%
H: 1.12%
C: -1.31%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 1.05%
H: 1.98%
C: -6.88%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
covid-19 treatment fda application covid authorization merge emergency use authorization
FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.73%
H: 0.13%
C: -0.44%
new drug fda drug hiv application granted grant
GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors
Published: 2021-08-17 (Crawled : 21:00) - prnewswire.com
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.17%
H: 0.66%
C: -0.59%
fda solid tumors approval dostarlimab
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
Published: 2021-05-26 (Crawled : 23:00) - globenewswire.com
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.8%
H: 0.69%
C: 0.23%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.17%
H: 0.36%
C: -0.72%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 4.2%
H: 0.3%
C: -9.4%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.5%
H: 0.32%
C: -1.27%
covid treatment fda risk biotech technology iot merge authorized emergency use authorization
ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV
Published: 2021-05-04 (Crawled : 13:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.43%
H: 0.43%
C: -0.13%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.19%
H: 0.29%
C: -0.27%
new drug fda drug hiv submission application
FDA grants accelerated approval for GSK's JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
Published: 2021-04-22 (Crawled : 21:00) - biospace.com/
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.15%
H: 0.36%
C: -0.34%
fda women cancer trial approval granted grant dostarlimab
GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19
Published: 2021-03-26 (Crawled : 13:00) - globenewswire.com
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.28%
H: 2.0%
C: 1.95%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.52%
H: 1.01%
C: 0.68%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 1.27%
H: 1.56%
C: -3.45%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.31%
H: 1.33%
C: 1.22%
covid treatment fda biotech technology iot merge submission authorized emergency use authorization
FDA approves GSK's BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
Published: 2020-12-17 (Crawled : 14:12) - prnewswire.com
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 1.44%
H: 0.16%
C: -0.19%
fda lupus fda approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.